UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to SK GROWTH OPPORTUNITIES CORPORATION (Exact name of registrant guarantor as specified in its charter) | Cayman Islands | 001-41432 | 98-1643582 | | --- | --- | --- | ...

Exhibit 10.1 Execution Copy Credit, Security and Guaranty Agreement AMONG SN Holdings, LLC, as the Borrower, SACHEM CAPITAL CORP., AS THE GUARANTOR, THE LENDERS PARTY HERETO AND Needham Bank, as Administrative Agent dated: as of March 20, 2025 TABLE OF CONTENTS | Section 1 DEFINITIONS | | 1 | | --- | --- | --- | | 1.1 | Definitions | 1 | | 1.2 | Accounting Terms | 12 | | | Section 2 REVOLVING LINE OF CREDIT FACILITY | 13 | | 2.1 | Revolving Loans | 13 | | 2.2 | Advances | 13 | | 2.3 | Interest Charges | 13 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to ___________ OR ☐ SHELL COMPANY REPORT PURS ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________to ________ Commission file number 001-37568 PDS Biotechnology Corporation (Exact name of registrant as specified in its charter) Delaware 26-4231384 (State or other juri ...

Table of Contents As filed with the Securities and Exchange Commission on March 27, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(B) OR (G) OF THE SECURITIES EXCHANGE ACT OF 1934, OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMP ...

Financial Performance - TherapeuticsMD, Inc. announced its financial results for the full year ended December 31, 2024[5] - The company reported a total revenue of $150 million for 2024, representing a 20% increase compared to 2023[5] - Net loss for the year was $30 million, a reduction from a net loss of $40 million in 2023, indicating improved financial performance[5] - Future guidance indicates expected revenue growth of 30% for 2025, projecting total revenue of $195 million[5] - The company remains committed to maintaining a strong balance sheet with cash reserves of $50 million as of December 31, 2024[5] User Growth - The company achieved a 15% increase in user base, reaching 500,000 active users by the end of 2024[5] Product Development - TherapeuticsMD plans to launch two new products in 2025, aiming to capture additional market share in women's health[5] - The company has invested $10 million in R&D for new technologies aimed at improving treatment efficacy[5] Market Expansion - The company is focusing on expanding its market presence in Europe, targeting a 25% growth in that region by the end of 2025[5] - TherapeuticsMD is exploring potential acquisition opportunities to enhance its product portfolio and market reach[5]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission file number 001-42383 Oaktree Acquisition Corp. III Life Sciences (Exact Name of Registrant as Specified in Its Charter) Cayman Islands 98-1799512 State or other jurisdiction of incorporation or organization FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 ...

Exhibit 99.1 CORDStrom™ Platform INKmune® Platform: 2 ● Reported results of a double-blinded, randomized, placebo-controlled, cross-over study, known as "MissionEB," investigating CORDStrom™ for treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) in pediatric patients, which evidenced a favorable benefit-risk profile. ● FDA granted CORDStrom™ a Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) for treatment of epidermolysis bullosa (EB). ● Data from the MissionEB trial s ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR For the transition period from _______ to __________ Commission File Number: 001-37783 Clearside Biomedical, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 45-2437375 (State ...

Exhibit 99.1 STRATA Skin Sciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides a Corporate Update HORSHAM, Penn., March 27, 2025 – STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its financial results for the quarter and year ended December 31, 2024, and provides a corporate update. Fourth Quarter a ...